SS
TRVI icon

SBI Securities’s Trevi Therapeutics TRVI Stock Holding History

SBI Securities’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224 Sell
12
-17
-59% -$247 ﹤0.01% 3291
2026
Q1 		$346 Buy
+29
New +$325 ﹤0.01% 3025
2025
Q4 		– Sell
-117
Closed -$1.07K – 4226
2025
Q3 		$1.07K Buy
+117
New +$877 ﹤0.01% 2662
2025
Q1 		– Sell
-68
Closed -$280 – 4202
2024
Q4 		$280 Buy
+68
New +$218 ﹤0.01% 3121

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

SBI Securities's TRVI Position: Q2 2026 in Review

SBI Securities reduced its Trevi Therapeutics (TRVI) stake by 59% in Q2 2026, selling an estimated $247 and leaving 12 shares worth $224. The position accounts for ﹤0.01% of the portfolio, ranked #3291.

SBI Securities first reported a position in TRVI in Q4 2024 and has held it in 4 quarters since. The position peaked at $1.07K in Q3 2025. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • SBI Securities held 12 shares of Trevi Therapeutics worth $224 as of Q2 2026.
  • SBI Securities sold 17 Trevi Therapeutics shares in Q2 2026, an estimated $247.
  • Trevi Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3291 holding.
  • SBI Securities first reported a position in Trevi Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • SBI Securities's Trevi Therapeutics position peaked at $1.07K in Q3 2025.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.